Effect of Lymphadenectomy on Survival in Early-Stage Type II Endometrial Carcinoma and Carcinosarcoma.


Journal

Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537

Informations de publication

Date de publication:
2020
Historique:
received: 07 10 2019
revised: 28 02 2020
accepted: 21 03 2020
entrez: 1 5 2020
pubmed: 1 5 2020
medline: 1 5 2020
Statut: epublish

Résumé

We aimed to investigate whether systematic pelvic and paraaortic lymph node dissection delivers any survival advantage in a subgroup of patients with type II endometrial carcinoma and carcinosarcoma. We evaluated 135 patients with clinically early-stage (Stage I-II) type II endometrial carcinoma and carcinosarcoma who underwent systematic pelvic and paraaortic lymph node dissection or who did not undergo any lymph node dissection. Overall survival (OS) and recurrence-free survivals (RFS) were significantly longer in the systematic lymph node dissection group (hazard ratio 0.28, 95% CI 0.13-0.62 Systematic pelvic and paraaortic lymph node dissection independently and significantly prolongs the survival of patients with early-stage type II endometrial carcinoma and carcinosarcoma.

Identifiants

pubmed: 32351564
doi: 10.1155/2020/1295613
pmc: PMC7171670
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1295613

Informations de copyright

Copyright © 2020 Dogan Vatansever et al.

Déclaration de conflit d'intérêts

The authors declare that there are no conflicts of interest associated with this study.

Références

Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Lancet Oncol. 2019 Sep;20(9):1273-1285
pubmed: 31345626
J Obstet Gynaecol Res. 2014 Feb;40(2):312-6
pubmed: 24472048
Lancet. 2010 Apr 3;375(9721):1165-72
pubmed: 20188410
Int J Gynecol Cancer. 2008 Mar-Apr;18(2):255-61
pubmed: 17624991
Int J Gynecol Cancer. 2014 Jul;24(6):1033-41
pubmed: 24905617
Jpn J Clin Oncol. 2012 May;42(5):405-12
pubmed: 22396619
Eur J Cancer. 2010 Sep;46(13):2422-31
pubmed: 20619634
Gynecol Oncol. 2013 Sep;130(3):441-5
pubmed: 23747331
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Ann Oncol. 2016 Jan;27(1):16-41
pubmed: 26634381
Int J Gynecol Cancer. 2012 May;22(4):611-6
pubmed: 22398712
Ann Surg Oncol. 2014 Aug;21(8):2755-61
pubmed: 24705578
Gynecol Oncol. 2008 Apr;109(1):11-8
pubmed: 18304622
J Gynecol Oncol. 2015 Jan;26(1):25-31
pubmed: 25376917
Int J Gynecol Cancer. 2011 Feb;21(2):332-6
pubmed: 21270614
Ann Surg Oncol. 2014 Jul;21(7):2376-82
pubmed: 24590435
Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):845-57
pubmed: 25817745
Clin Nucl Med. 2015 Oct;40(10):780-5
pubmed: 26053711
Gynecol Oncol. 2011 Dec;123(3):542-7
pubmed: 21963091

Auteurs

Dogan Vatansever (D)

Department of Obstetrics and Gynecology, Gynecologic Oncology Division, Koc University School of Medicine, Istanbul, Turkey.

Hamdullah Sozen (H)

Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul University, Istanbul, Turkey.

Gulcin Sahin Ersoy (G)

Department of Obstetrics and Gynecology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, Istanbul, Turkey.

Burak Giray (B)

Department of Obstetrics and Gynecology, Zeynep Kamil Education and Research Hospital, Istanbul, Turkey.

Samet Topuz (S)

Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul University, Istanbul, Turkey.

A Cem Iyibozkurt (AC)

Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul University, Istanbul, Turkey.

Yavuz Salihoglu (Y)

Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul University, Istanbul, Turkey.

Classifications MeSH